Effects of Odanacatib on BMD and overall safety in the treatment of Osteoporosis in postmenopausal women previously treated with Alendronate — ASN Events
  1. Schedule
  2. ESA Clinical-Basic Orals - Bone/Muscle
  3. Effects of Odanacatib on BMD and overall safety in the treatment of Osteoporosis in postmenopausal women previously treated with Alendronate

Effects of Odanacatib on BMD and overall safety in the treatment of Osteoporosis in postmenopausal women previously treated with Alendronate (#52)

Elisabeth Smith 1 , Roland Chapurlat 2 , Tobias De Villiers 3 , Sydney Bonnick 4 , Alberto Odio 5 , Santiago Palacios 6 , Boyd B Scott 1 , Celine Le Bailly De Tilleghem 1 , Carolyn DaSilva 1 , Albert Leung 1 , Deborah Gurner 1
  1. Merck, Sharpe & Dohme Corp., Whitehouse Station, New Jersey, USA
  2. INSERM U1033, Université de Lyon, Hôpital E Herriot, Lyon, France
  3. Dept of Obstetrics and Gynaecology, Mediclinic Panorama, Stellenbosch University, Cape Town, South Africa
  4. Research Center of North Texas , Denton, TEXAS, USA
  5. Alto California Medical Group, Simi Valley, California, USA
  6. Salud y Medicina de la Mujer C/Antonio Acuña, Instituto Palacios, Madrid, Spain
Publish consent withheld
@ESASRB